Related Experiment Video

Updated: Jun 25, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Cyclin-dependent kinase inhibitors as potential targeted anticancer agents

Ivan Diaz-Padilla1, Lillian L Siu, Ignacio Duran

  • 1Medical Oncology Department, Centro Integral Oncologico Clara Campal, C/ Oña 10, 28050, Madrid, Spain.

Investigational New Drugs
|March 6, 2009
PubMed

Insights

Cyclin-dependent kinases (CDKs) are crucial for cell cycle progression and often dysregulated in cancer. This review highlights CDK inhibitors as promising anticancer drug targets, focusing on newer agents in clinical development.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) regulate cell cycle transitions, essential for normal cell proliferation.
  • Aberrant CDK activity is a common feature in human cancers, driving uncontrolled cell growth.
  • CDKs and associated proteins are validated targets for anticancer drug discovery.

Purpose of the Study:

  • To review key cyclin-dependent kinase (CDK) inhibitors.
  • To emphasize novel CDK inhibitors currently in clinical development.
  • To discuss the biological rationale underpinning CDK-targeted cancer therapy.

Main Methods:

  • Literature review of CDK inhibitors.
  • Analysis of clinical trial data for emerging CDK-targeting drugs.
  • Examination of the molecular mechanisms of CDK regulation in cancer.

Main Results:

  • Several classes of CDK inhibitors are under investigation.
  • Newer CDK inhibitors demonstrate promising efficacy in early clinical trials.
  • Targeting specific CDKs offers a rational approach to cancer treatment.

Conclusions:

  • CDK inhibitors represent a significant therapeutic strategy in oncology.
  • Ongoing research focuses on optimizing CDK inhibitor efficacy and safety.
  • Targeted CDK inhibition holds potential for personalized cancer medicine.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.